HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Gastroenterology
Sys. Review
Integrative review of Epimedium flavonoids in hepatitis and cirrhosis shows preclinical promise but lacks clinical validation
Ancient Herb Shows New Promise for Liver Scarring and Hepatitis
This integrative review synthesizes data from 33 high-impact studies regarding Epimedium species and its bioactive flavonoids, icariin and i…
This research suggests a traditional herb may offer a new way to protect the liver, but more work is needed to prove it’s safe and effective…
Frontiers
Apr 22, 2026
Psychiatry
Meta-analysis
Systematic review and meta-analysis on depression and anxiety prevalence in liver cirrhosis
More Than Half of Cirrhosis Patients Face Anxiety, New Global Study Reveals
This meta-analysis synthesized data from 23 studies including 979,113 patients with liver cirrhosis to estimate the prevalence of depression…
This massive global review proves that mental health struggles are a hidden, widespread crisis for people living with liver disease.
Frontiers
Apr 19, 2026
Diabetes & Endocrinology
Observational study links semaglutide dose and weight loss to lower liver disease risk
Study links semaglutide use to lower risk of several liver conditions in patients with liver disease
This observational study from a real-world federated EHR network analyzed 6,734 patients with liver disease.
Higher semaglutide doses and greater weight loss were linked to lower risks of steatohepatitis, alcoholic liver disease, and death in patien…
medRxiv
Apr 19, 2026
Neurology
Sys. Review
Review of liver disease immunomodulation strategies notes precision over broad suppression
Your Liver's Immune Cells Play Both Hero and Villain at Once
This narrative review examines immunomodulation approaches for liver diseases, including acute liver injury, HBV infection, MASLD/MASH, fibr…
Liver immune cells can both damage and repair your organ at the same time, a discovery that could unlock new precision treatments for hepati…
Frontiers
Apr 18, 2026
Oncology
Meta-analysis
Meta-analysis links rare APOB variants to advanced MASLD, cirrhosis, and hepatocellular carcinoma across large cohorts
Do rare gene changes linked to liver disease also raise your risk for cancer and scarring?
This meta-analysis reviews data from the Million Veteran Program, UK Biobank, and clinical cohorts to assess rare APOB variant carriage in p…
Rare gene changes linked to fatty liver disease also raise your risk for liver cancer and severe scarring, according to new findings.
Apr 16, 2026
Gastroenterology
Meta-analysis
Network meta-analysis compares preventive measures for esophageal variceal bleeding in 6510 cirrhosis patients
New Combo Stops Bleeding Better Than Old Drugs
This network meta-analysis synthesizes data from 6510 patients with liver cirrhosis and esophageal varices regarding primary preventive meas…
Combining two specific medicines stops dangerous stomach bleeding better than older single-drug treatments for people with advanced liver sc…
Frontiers
Apr 16, 2026
Diabetes & Endocrinology
Cohort
PON1 genetic variants rs2057681 and rs854572 modulate PONase activity and dysmetabolic risk in MASLD
Your Liver's Hidden Genetic Shield
This cohort study of 922 Portuguese individuals from the PREVADIAB2 cohort examined associations between PON1 genetic variants and metabolic…
Your specific DNA pattern for a liver enzyme predicts diabetes and liver scarring risk better than simple blood tests alone.
medRxiv
Apr 16, 2026
Nutrition & Obesity Medicine
Sys. Review
Review of bile acid homeostasis regulation in liver disease and cancer
Review of bile acid regulation for liver disease conditions shows limited evidence
This narrative review examines the regulation of bile acids homeostasis in conditions including cholestasis, hepatic fibrosis, cirrhosis, he…
Bile acid imbalance drives liver disease, but this review found no data proving that regulating it safely treats conditions like cirrhosis o…
Frontiers
Apr 15, 2026
Gastroenterology
RCT
Seladelpar shows improved composite endpoint and ALP reduction in PBC with compensated cirrhosis
New Drug Helps Liver Disease Patients With Cirrhosis
A phase 3 RCT program (RESPONSE and ASSURE studies) in patients with primary biliary cholangitis and compensated cirrhosis found seladelpar …
A new drug lowers liver stress markers in patients with cirrhosis, offering hope where older medicines often failed to stop disease progress…
Apr 14, 2026
Pulmonology & Critical Care
Cohort
Non-cirrhotic portal fibrosis identified in 32.6% of pre-cirrhotic primary biliary cholangitis patients in a retrospective analysis
Hidden Liver Damage Found in Early PBC
This retrospective analysis examined 92 biopsy-proven pre-cirrhotic primary biliary cholangitis (PBC) patients to characterize non-cirrhotic…
Many people with primary biliary cholangitis develop hidden liver damage called non-cirrhotic portal fibrosis before permanent scarring begi…
Frontiers
Apr 13, 2026
Gastroenterology
Meta-analysis
Machine learning models show moderate to high accuracy for predicting variceal bleeding in cirrhosis patients
New AI Tool Catches Bleeding Risks Early
A systematic review and meta-analysis of 21 studies involving 7,011 cirrhosis patients found machine learning models achieved pooled c-indic…
An AI tool now spots bleeding risks in liver disease earlier than current methods, helping doctors catch dangerous vein swelling before it t…
Apr 12, 2026
Gastroenterology
Meta-analysis
Nurse-assisted outpatient follow-up reduces 30-day readmissions but not mortality in decompensated cirrhosis
Nurse Care Cuts Hospital Returns for Liver Patients
A meta-analysis of 668 patients with decompensated liver cirrhosis found nurse-assisted outpatient follow-up significantly reduced 30-day re…
Adding nurses to liver care teams significantly cuts 30-day hospital readmissions and improves outcomes for patients with advanced liver dis…
Apr 10, 2026
Questions about Cirrhosis
How common is depression among patients with liver cirrhosis?
Depression is very common in liver cirrhosis, affecting about 37% of patients globally, yet it often goes undiagnosed.
Full answer →Can the Patient Buddy App help reduce hospital readmissions for my cirrhosis?
Yes, the Patient Buddy App reduced avoidable hospital readmissions in cirrhosis patients by about half in a clinical trial, but discuss with your doctor if it's right for you.
Full answer →